Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Alkermes Plc

APT Therapeutics, Inc.

Mabtech Limited

Philogen S.p.A.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Overview 6

Therapeutics Development 7

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Stage of Development 7

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Therapy Area 8

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Indication 9

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Products under Development by Companies 12

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development 21

AbbVie Inc 21

Alkermes Plc 22

APT Therapeutics, Inc. 23

Mabtech Limited 24

Philogen S.p.A. 25

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles 26

ALKS-4230 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

APT-602 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

basiliximab - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

basiliximab biobetter - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

daclizumab - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Darleukin - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Recombinant Protein to Agonize IL2RA, IL2RB and IL2RG for Autoimmune Diseases - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Projects 40

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Featured News & Press Releases 42

Sep 15, 2016: New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA (Daclizumab) and Support Long-Term Safety Profile 42

Sep 08, 2016: Biogen Demonstrates Data on ZINBRYTA at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis 44

Aug 15, 2016: Diplomat to Dispense ZINBRYTA for the Treatment of Multiple Sclerosis 45

Jul 05, 2016: Biogen and AbbVie’s Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis 45

May 27, 2016: Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosi 47

May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 48

Apr 29, 2016: Biogen and Abbvie Receive Positive Opinion From The CHMP on ZINBRYTA (daclizumab) For Treatment Of Multiple Sclerosis 49

Apr 22, 2016: Daclizumab Demonstrates Significant, Sustained Improvements In Cognition Compared To Interferon Beta-1A IM 50

Apr 20, 2016: Data Presented at AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action 51

Apr 12, 2016: Biogen to Present Data on ZINBRYTA at 2016 AAN Annual Meeting 53

Jan 21, 2016: Philogen Announces Commencement of Phase III Pivotal Trial in Melanoma 53

Oct 20, 2015: Results Published from a Phase 3 Trial of Daclizumab High-Yield Process (DAC HYP) in Relapsing MS 54

Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS 55

Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress 58

Apr 29, 2015: FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS 58

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by AbbVie Inc, H2 2016 21

Pipeline by Alkermes Plc, H2 2016 22

Pipeline by APT Therapeutics, Inc., H2 2016 23

Pipeline by Mabtech Limited, H2 2016 24

Pipeline by Philogen S.p.A., H2 2016 25

Dormant Projects, H2 2016 40

Dormant Projects (Contd..1), H2 2016 41

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared